FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Ranbaxy | Novartis | Glivec

Patent law won't marr India's industry

Tools

Novartis may be the only Big Pharma firm to pull the plug in India in the wake of the Glivec patent fight. You'll recall that an Indian court wouldn't grant Novartis protection for Glivec, citing laws that prohibit patenting drugs that offer only marginal improvements over existing products. Novartis then said it was canceling plans to invest hundreds of millions in the country.

Meanwhile, though, other pharmaceuticals companies are forging right ahead. India's talent pool and cost profile make it too attractive, analysts say. Plus, several companies are deeply entrenched in manufacturing and/or research partnerships with Indian companies such as Ranbaxy

- read the report on India from the Business-Standard

Related Articles:
Novartis backs out of India R&D deal. Report
Indian court spurns Novartis on patent challenge. Report
Novartis patent challenge spurs protests in India. Report
India patent ruling won't face the WTO. Report

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Ranbaxy   Novartis   Glivec  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.